Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P78314
UPID:
3BP2_HUMAN
Alternative names:
-
Alternative UPACC:
P78314; A6NNC2; B2R5R6; B4DT04; D3DVR0; D6R919; O00500; O15373; P78315
Background:
SH3 domain-binding protein 2 plays a pivotal role in signal transduction pathways by differentially binding to the SH3 domains of specific proteins. Its interaction with phosphatidylinositols connects the hemopoietic tyrosine kinase fes to the cytoplasmic membrane, a process that is phosphorylation dependent.
Therapeutic significance:
The protein is implicated in Cherubism, a syndrome marked by excessive bone degradation and fibrous tissue mass development in the jaws, starting typically around three years of age. Understanding the role of SH3 domain-binding protein 2 could lead to novel therapeutic strategies for this condition.